Anabolic agents: what is beyond osteoporosis?

Area of Science:

• Endocrinology
• Orthopedics
• Pharmacology

Background:

• Osteoporosis is a skeletal disorder marked by low bone mass and increased fracture risk.
• Anabolic agents stimulate osteoblasts to increase bone mass and reduce fracture risk.
• Teriparatide (TPTD) and abaloparatide (APPTD) are approved for high-risk osteoporosis but have off-label uses.

Purpose of the Study:

• To summarize the scientific literature on the efficacy, effectiveness, and safety of TPTD in off-label settings.
• To evaluate TPTD's potential in spine fusion, osteonecrosis of the jaw, arthroplasty, and fracture healing.

Main Methods:

• Systematic review of scientific literature.
• Analysis of studies on TPTD's use in various orthopedic and dental conditions.
• Evaluation of efficacy, effectiveness, and safety data.

Main Results:

• TPTD demonstrates potential benefits in off-label applications such as spine fusion and fracture healing.
• Evidence for efficacy and safety in osteonecrosis of the jaw and arthroplasty requires further investigation.
• TPTD's anabolic properties support its use in bone regeneration.

Conclusions:

• TPTD shows promise for off-label use in specific settings beyond osteoporosis treatment.
• Further research is needed to establish definitive guidelines for TPTD in these applications.
• Anabolic agents like TPTD represent a valuable therapeutic option for bone repair and regeneration.